Glaukos Corp
GKOS83.470USD
-2.370-2.76%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
4.78BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Glaukos Corp Unternehmen
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Unternehmensinformationen
BörsenkürzelGKOS
Name des UnternehmensGlaukos Corp
IPO-datumJun 25, 2015
CEOMr. Thomas William Burns
Anzahl der mitarbeiter995
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse1 Glaukos Way
StadtALISO VIEJO
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl92656
Telefon19493679600
Websitehttps://www.glaukos.com
BörsenkürzelGKOS
IPO-datumJun 25, 2015
CEOMr. Thomas William Burns
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.50M
-0.34%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
69.52K
+56.16%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
56.36K
+3.89%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.23K
+4.47%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.18K
+6.19%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
32.88K
-13.52%
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.50M
-0.34%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
69.52K
+56.16%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
56.36K
+3.89%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.23K
+4.47%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.18K
+6.19%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
32.88K
-13.52%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Glaucoma
88.14M
82.63%
Corneal Health
18.53M
17.37%
Nach RegionUSD
Name
Umsatz
Anteil
United States
75.07M
70.38%
International
31.59M
29.62%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Glaucoma
88.14M
82.63%
Corneal Health
18.53M
17.37%
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.77%
The Vanguard Group, Inc.
10.63%
Fidelity Management & Research Company LLC
9.14%
Wellington Management Company, LLP
5.66%
State Street Global Advisors (US)
3.64%
Andere
57.16%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.77%
The Vanguard Group, Inc.
10.63%
Fidelity Management & Research Company LLC
9.14%
Wellington Management Company, LLP
5.66%
State Street Global Advisors (US)
3.64%
Andere
57.16%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
56.50%
Investment Advisor/Hedge Fund
34.87%
Hedge Fund
9.09%
Individual Investor
3.31%
Pension Fund
2.57%
Research Firm
1.75%
Sovereign Wealth Fund
1.40%
Bank and Trust
1.12%
Family Office
0.05%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
638
61.06M
106.48%
+15.37K
2025Q1
643
60.20M
105.40%
-1.30M
2024Q4
610
59.75M
105.65%
+533.86K
2024Q3
567
57.47M
104.31%
-894.95K
2024Q2
545
56.86M
103.79%
-713.22K
2024Q1
509
54.47M
110.12%
-1.91M
2023Q4
480
53.71M
109.34%
-1.79M
2023Q3
475
52.90M
108.58%
-1.85M
2023Q2
486
51.69M
106.83%
-2.99M
2023Q1
490
50.54M
105.57%
-3.20M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
7.64M
13.38%
-218.59K
-2.78%
Mar 31, 2025
The Vanguard Group, Inc.
5.95M
10.42%
-9.86K
-0.17%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.57M
9.74%
+417.67K
+8.11%
Mar 31, 2025
Wellington Management Company, LLP
2.29M
4.01%
+131.25K
+6.08%
Mar 31, 2025
State Street Global Advisors (US)
1.98M
3.47%
-79.01K
-3.83%
Mar 31, 2025
PRIMECAP Management Company
1.22M
2.13%
+4.15K
+0.34%
Mar 31, 2025
Burns (Thomas William)
1.50M
2.62%
-5.16K
-0.34%
May 27, 2025
Geode Capital Management, L.L.C.
1.22M
2.13%
+17.85K
+1.49%
Mar 31, 2025
AllianceBernstein L.P.
1.28M
2.24%
+461.39K
+56.53%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.08M
1.9%
+277.03K
+34.32%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
Invesco S&P SmallCap Health Care ETF
3.32%
Alger Weatherbie Enduring Growth ETF
2.15%
SPDR S&P Health Care Equipment ETF
1.9%
ROBO Global Healthcare Technology & Innovation ETF
1.59%
Invesco S&P SmallCap Momentum ETF
1.42%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.86%
SPDR S&P 600 Small Cap Growth ETF
0.86%
OneAscent Small Cap Core ETF
0.68%
iShares U.S. Medical Devices ETF
0.67%
iShares S&P Small-Cap 600 Growth ETF
0.67%
Mehr Anzeigen
Invesco S&P SmallCap Health Care ETF
Anteil3.32%
Alger Weatherbie Enduring Growth ETF
Anteil2.15%
SPDR S&P Health Care Equipment ETF
Anteil1.9%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.59%
Invesco S&P SmallCap Momentum ETF
Anteil1.42%
Vanguard S&P Small-Cap 600 Growth Index Fund
Anteil0.86%
SPDR S&P 600 Small Cap Growth ETF
Anteil0.86%
OneAscent Small Cap Core ETF
Anteil0.68%
iShares U.S. Medical Devices ETF
Anteil0.67%
iShares S&P Small-Cap 600 Growth ETF
Anteil0.67%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
